Semaglutide: The Evidence-First Guide for Self-Experimenters
A plain-English, evidence-led rundown of semaglutide: how it works, what the big trials actually showed for weight, glucose and heart risk, and the catches.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Research Rats summary
Plain-English overview — free for everyone.
Semaglutide is a GLP-1 receptor agonist — a prescription medicine that mimics a gut hormone released after eating. It is approved for type 2 diabetes and for weight management, sold under names like Ozempic, Wegovy and Rybelsus.
Unusually for this space, the evidence is genuinely strong: large, high-quality randomised trials show substantial weight loss, better blood-sugar control, and — in people with heart disease but without diabetes — about a 20% reduction in major cardiovascular events.
Two honest caveats: the benefits depend on continued use (most of the weight returns after stopping), and gastrointestinal side effects are common. For anyone outside a regulated pharmacy supply, the biggest unknown is the product itself — the trial safety record belongs to regulated medicine, not to material sold as 'research' semaglutide.
At a glance
- Compound class
- GLP-1 receptor agonist (incretin mimetic)
- Primary pathway / target
- GLP-1 receptor (incretin signalling)
- Main research interest
- Type 2 diabetes, weight management, cardiovascular risk reduction
- Regulatory status
- Approved medicine
Evidence signals
shown separately — never one score
Community signal reflects how much a compound is discussed online — not how strong the evidence is.
- Common online interest
- Weight loss, appetite control, 'GLP-1' discussion
- Major caution themes
- GI adverse effectsThyroid C-cell boxed warning (rodent)Benefit reverses on stoppingMuscle-mass lossGrey-market supply/purity
Research Rats interpretation
An unusually well-evidenced metabolic medicine — large, high-quality human trials support weight, glycaemic and cardiovascular benefit. The main real-world risk for self-experimenters is unregulated, non-pharmacy 'research' supply, not the molecule itself.
Evidence gap
The strongest evidence applies to specific licensed uses — type 2 diabetes, weight management, and cardiovascular risk in people with established heart disease — not to general wellness or optimisation. Trial benefits also depend on continued use and largely reverse after stopping.
This page helps interpret evidence. It does not provide dosing, protocol, reconstitution, injection, sourcing, stack, cycle, suitability, or medical advice.
Evidence profile
Assessed 2026-06-13Among the best-evidenced metabolic drugs: large top-tier RCTs for weight and glycaemia plus a ~20% cardiovascular event reduction. Benefits depend on continued use; for self-experimenters the main caveat is compounded/grey-market supply, not the science.
Well-understood GLP-1 receptor agonism; an albumin-binding fatty-acid chain gives weekly dosing.
Mechanism established; the profile is defined by its large human trial programme rather than animal data.
Large placebo-controlled RCTs (STEP, SUSTAIN) and a dedicated cardiovascular outcomes trial (SELECT, n=17,604) in top-tier journals.
~15–16% weight loss, glycaemic control, and a ~20% reduction in major adverse cardiovascular events (SELECT).
Well-characterised: FDA label and large trials; GI effects, pancreatitis/gallbladder signals, rodent-based thyroid C-cell boxed warning.
Approved and established (Ozempic / Wegovy / Rybelsus).
Very high for weight, glycaemia and cardiovascular benefit.
An approved prescription drug; the main concern is unregulated compounded / grey-market supply, not the molecule.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
An approved GLP-1 receptor agonist with an unusually strong human evidence base — large, well-powered, placebo-controlled randomised trials with hard endpoints for type 2 diabetes, weight management and, in people with established cardiovascular disease but no diabetes, cardiovascular events.
Safety snapshot
The common adverse effects are gastrointestinal and usually dose-related; the documented profile also includes pancreatitis, gallbladder disease, dehydration-related acute kidney injury and diabetic-retinopathy complications, a rodent-based thyroid C-cell boxed warning of uncertain human relevance, and lean-mass loss with rapid weight reduction. The benefit reverses on stopping, and the trial safety record belongs to regulated product, not to compounded or 'research' material.
Regulatory & legality
Approved medicineAn approved prescription medicine (marketed as Ozempic, Wegovy and Rybelsus) whose dosing is regulated and medically supervised; material sold outside regulated pharmacy supply as compounded or 'research' semaglutide is not the approved product and is of unverified purity, concentration and sterility.
Where claims can exceed the evidence
The strong evidence is for supervised use of the regulated product; it does not establish the safety of unsupervised use or of grey-market/compounded material, and the weight benefit is treatment-dependent rather than a one-off cure.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Semaglutide is one of the rare compounds in this space where the evidence is genuinely heavyweight. It is not a research chemical with a handful of rodent studies behind it; it is an approved prescription drug sitting on top of one of the strongest human-trial datasets of any metabolic medicine — large, well-powered, placebo-controlled randomised trials published in the top-tier journals (NEJM, JAMA, the Lancet, Nature Medicine), with hard clinical endpoints rather than surrogate hand-waving.
The headline numbers are striking. In obesity trials, semaglutide drove mean weight loss of roughly 15 to 16% over 68 weeks [3], with that effect holding at the two-year mark [5]. In people with overweight or obesity and established heart disease but no diabetes, it cut major adverse cardiovascular events by about 20% [11]. Those are results that reshape how a whole field thinks.
Safety note
Key cautions:
- Boxed warning on the FDA label for thyroid C-cell tumours, based on rodent data. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Human relevance remains uncertain [14].
- Effects are largely reversible on stopping — the STEP 1 extension showed most weight and metabolic gains revert, which implies long-term, potentially indefinite use for sustained benefit [6].
- Not for use in pregnancy. Caution is needed in certain populations, such as those with severe GI disease.
- Source matters enormously. Purity, dosing accuracy, and sterility are major concerns with compounded or non-pharmaceutical "research-grade" semaglutide bought outside regulated supply chains. The trial safety data come from regulated products and may not apply to unregulated sources.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
The full research report — members
- Mechanism Deep Dive
- Clinical / Human Evidence
- Preclinical Evidence
- Dose and Exposure Data
- Expert Commentary
- Community Interpretation
- Evidence Interpretation
- Research Gaps
- References
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Tirzepatide: The Dual-Incretin Heavyweight, Examined
A clear-eyed look at tirzepatide — the dual GIP/GLP-1 agonist with one of the strongest human-trial records in metabolic medicine.
same mechanism
Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It
An evidence-first look at retatrutide, the investigational GLP-1/GIP/glucagon triple agonist posting the largest weight-loss numbers seen in any incretin trial to date.
same compound class
Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
same goal
Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.